Opens in a new tab

In vitro diagnostic kit for the simultaneous detection of the G20210A mutation in the prothrombin gene (FII) and the G1691A mutation in Factor V using real-time PCR.

Detailed description

Operating principle

The assay is based on the real-time PCR (Real-Time PCR) amplification of specific regions of the FII and FV factor genes containing the mutations of interest. It uses TaqMan® hydrolysis probes labelled with fluorophores (FAM, HEX, ROX and Cy5) that enable allelic discrimination. The fluorescent signal generated during amplification is proportional to the amplified DNA and enables genotype determination.

Clinical applications

Qualitative detection of the G20210A (FII) and G1691A (Factor V Leiden) mutations, associated with the risk of venous thrombosis and inherited thrombophilia.

Key aspects and benefits

Multiplex detection: both mutations are detected simultaneously in a single reaction (G20210A and G1691A).
High specificity
Clear fluorescence-based interpretation
Compatible with multiple real-time PCR instruments

Key indicators

100% Concordance
100% Repeatability and reproducibility
High Analytical specificity

Intended users

Technical personnel trained and qualified in molecular biology and genetic analysis in specialised clinical laboratories.

Considerations or limitations

Detects only the specified mutations Variants in primer- or probe-binding regions may affect the interpretation of results. The results must be used together with other clinical and laboratory data.
Presentation details
Available references
GVS-FIIFV-24 24 tests.
GVS-FIIFV-48 48 tests.
GVS-FIIFV-96 96 tests (on request).
Kit contents: each kit contains Master Mix, the primer mixture (Primer Mix), controls (WT and MUT), and a reaction blank (Reaction Blank).
Storage conditions: Store between -30°C and -18°C.

Area:

Hematology
Consult our experts

Google reCaptcha: Invalid site key.

Related products

FUSIONPlex™ Heme v3 & Pan-Heme v2

RNA-based next-generation sequencing solution for the analytically sensitive identification of known and novel gene fusions, splicing variants, exon-skipping events, SNVs/Indels and gene expression in haematological malignancy research. FUSIONPlex Pan-Heme v2 provides broad coverage of 218 genes associated with haematological malignancies, while FUSIONPlex Heme v3 provides more focused coverage of 121 genes targeting alterations frequently found…
Archer Dx
Next Generation Sequencing (NGS)

Tapestri™

The Tapestri® platform enables the simultaneous integration of three biological dimensions from the same individual cell: DNA, RNA and surface proteins. This unprecedented multi-omics capability provides a direct and functional view of how specific genetic alterations (genotype) shape transcriptional expression and protein behaviour (phenotype), without the need to reconcile data from separate platforms. Conventional high-throughput…
Mission Bio
Single cell Sequencing

Violet 3.0 & QF-Pro® Technology

Conventional spatial biology reveals where proteins are; Violet 3.0 and QF-Pro® technology reveal what they are doing. Most current proteomic assays are limited to measuring molecular expression levels, overlooking whether proteins are actually activated or interacting with one another. In critical fields such as immuno-oncology, neurobiology and drug development, the relationship between expression and the…
Hawk Biosystem
Functional Assay

Beacon® Optofluidic Suite

The Beacon® Optofluidic Suite represents an absolute revolution in cell biology and biotherapeutic development. By synergistically integrating advanced microfluidics, precision optics, optoelectronics and artificial intelligence, this platform enables the isolation, culture, characterization and recovery of thousands of individual cells in a fully automated manner and in real time. Unlike traditional static or destructive methodologies, Bruker’s…
Bruker
Functional Assay